Tovecimig Plus Paclitaxel Improves Tumor Response and Progression-Free Survival in Biliary Tract Cancer
A first-in-class bispecific antibody paired with paclitaxel more than tripled response rates in previously treated biliary tract cancer, but overall survival did not improve.
Summary
Biliary tract cancer is an aggressive malignancy with few options once first-line chemotherapy stops working. The COMPANION-002 trial tested tovecimig, an experimental antibody that blocks two tumor blood-vessel growth signals (VEGF-A and DLL4), combined with the chemotherapy drug paclitaxel. In 168 patients who had already received gemcitabine and cisplatin, 18.0% responded to the combination versus 5.3% on paclitaxel alone. Median time before the cancer progressed rose from 2.6 to 4.7 months. However, overall survival was essentially the same, 8.9 versus 9.4 months. Crossover to the combination after progression in the paclitaxel-only group may have blurred that comparison. Experts called the results encouraging but said a larger phase III trial against the FOLFOX regimen would be ideal. The findings were presented at ESMO and published in the Journal of Clinical Oncology.
Detailed Summary
Biliary tract cancers, which arise in the bile ducts and gallbladder, are aggressive and becoming more common. Patients with advanced disease have a median overall survival of about 12 months, and options are limited once first-line gemcitabine and cisplatin stop working. That leaves a high unmet need and a low bar for any new second-line therapy.
The COMPANION-002 phase II/III trial enrolled 168 patients with metastatic or locally advanced disease who had received one prior line of therapy. All had good performance status (ECOG 0 or 1), and those with known targetable mutations were excluded. Patients were randomized 2:1 to tovecimig plus paclitaxel or paclitaxel alone. Tovecimig is a first-in-class bispecific antibody that targets VEGF-A and DLL4, two signals tumors use to build blood supply.
The combination met its primary endpoint. Response rate was 18.0% versus 5.3% (P=0.0228), and median progression-free survival was 4.7 versus 2.6 months (HR 0.44, P<0.0001). Overall survival did not differ: 8.9 versus 9.4 months (HR 1.05, P=0.77). Among the 57 patients on paclitaxel alone, 54% crossed over to the combination after progression. In those 31 patients, median PFS was 3.5 months after crossover versus 1.9 months before it, which suggests the drug has real activity. Crossover may also have confounded the survival comparison.
Invited discussant Sebastián Mondaca called the results encouraging but said it is unclear whether they will change practice. He would prefer a phase III trial with FOLFOX as the comparator showing a clear survival benefit. He also argued that tovecimig's activity and the high unmet need justify a formal review by guideline committees.
For patients and clinicians, this is a promising signal, not a new standard of care. Tovecimig remains investigational, the trial was small, and no overall survival gain was shown. Readers should check the full Journal of Clinical Oncology paper for safety data, subgroup results and the detailed crossover analysis.
Key Findings
- Tovecimig plus paclitaxel produced a 18.0% response rate versus 5.3% with paclitaxel alone in previously treated biliary tract cancer.
- Median progression-free survival improved to 4.7 months from 2.6 months (HR 0.44, P<0.0001).
- Overall survival showed no benefit: 8.9 versus 9.4 months (HR 1.05), possibly confounded by 54% crossover.
- After crossover, median PFS was 3.5 months versus 1.9 months before, supporting real drug activity.
- Experts want a phase III trial against FOLFOX before the combination could change clinical practice.
Methodology
This is a news report on a conference presentation (ESMO) of a randomized phase II/III trial, with simultaneous publication in the Journal of Clinical Oncology. MedPage Today is a reputable medical news outlet that includes independent expert commentary. The evidence is a randomized, open-comparator trial of 168 patients.
Study Limitations
The article is a brief news summary and truncates before reporting safety and adverse event data. The modest sample size, crossover confounding of overall survival, and lack of a FOLFOX comparator limit conclusions. Verify details in the Journal of Clinical Oncology publication.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: